

**MARYLAND PRESCRIPTION DRUG AFFORDABILITY STAKEHOLDER COUNCIL**  
**VIRTUAL MEETING**  
**Monday August 22, 2022**  
**Minutes**

**Agenda Item 1**

**Call to Order:**

Board Chair Van Mitchell called the meeting to order at 2:07 PM.

**Stakeholder Council Members present:** Allison Ciborowski, Jacqueline Allsup, Babette Edgar, PharmD., John Elliot, Jim Gutman, Deron Johnson, Barry Lipsy, Eric Morse, DDS, Marc Nicole, Shaun O'Brien, Hayley Park, Pharm. D., Stephen Rockower, MD, Martin Rosendale, Glenn Schneider, MPH, Sean Tunis, MD, MSc, Joseph Winn, Joey Mattingly, Pharm.D., MBA, PhD

**Agenda Item 2**

**Opportunity for Public Comment**

No persons registered for an opportunity to provide public comment.

**Agenda Item 3**

**Approval of Minutes**

The Chair moved this action item to the end of the agenda due to the initial lack of quorum.

**Agenda Item 4**

**Cost Review Process**

Executive Director Andrew York provided an overview of the cost review process outlined in Health-General Article § 21-2C-09. First, the Board identifies drugs that may create affordability issues using the statutory metrics and additional Board-identified metrics. Second, the Board determines whether to conduct a Cost Review for a specific drug (i.e., selects drug for Cost Review) and as part of that process receives input from the Stakeholder Council and considers “average cost share.” Third, in conducting the cost review the Board receives additional information and considers to the extent practicable 10 statutory factors and other factors identified by the Board. Fourth, the Board determines if the drug has or will create affordability challenges for the State healthcare system or high out-of-pocket costs. Council members asked questions and made comments about the process. Mr. York also discussed additional potential metrics for identifying drugs eligible for cost review including recommendations received through the comment process. The additional potential metrics include drugs with the highest overall spend, highest per-patient spend, highest patient out-of-pocket cost, highest price increase (percentage and gross), drugs reported by Maryland consumers as causing affordability issues, drugs approved through an FDA accelerated approval

pathway, only drug in class, highest advertising spend, and longest patent extensions. Mr. York encouraged the Stakeholder Council and the public to submit written comments about these potential metrics to the Board.

The presentation is available on the Board's website.

### **Agenda Item 5**

#### **Administrative Update**

Executive Director York discussed the Inflation Reduction Act and the provisions that impact prescription drug affordability.

### **Agenda Item 3 (Deferred)**

#### **Approval of Minutes**

Chair Mitchell asked for a motion to approve the June 27, 2022 minutes as submitted. Dr. Rockower moved the motion, Jim Gutman seconded, and the Stakeholder Council unanimously approved the minutes.

**Action: Minutes APPROVED.**

### **Agenda Item 6**

#### **Chair's Update**

The Chair advised that at the Council's October 24 meeting co-chairs for the Stakeholder Council will likely be announced and the role of focus groups will be discussed.

The Chair asked for a motion to adjourn the meeting.

Meeting was adjourned at 3:42 PM.